KOL | Kenneth TrippSepracor, Inc, Marlborough, Mass | Sepracor Inc, Marlborough, Massachusetts | Sepracor Inc., Marlborough, MA, USA |
KOL Resume for Kenneth Tripp
| Year | |
|---|---|
| 2008 | Sepracor, Inc, Marlborough, Mass |
| 2007 | Sepracor Inc, Marlborough, Massachusetts |
| 2006 | Sepracor Inc., Marlborough, MA, USA |
Kenneth Tripp: Influence Statistics
| Concept | World rank |
|---|---|
| hfa mdi improvements | #5 |
| events levalbuterol | #5 |
| mdi racemic | #5 |
| ralbuterol levels | #5 |
| adverse events levalbuterol | #5 |
| heart rate levalbuterol | #5 |
| 16 cumulative doses | #5 |
| rate ralbuterol | #5 |
| levalbuterol metereddose inhaler | #5 |
| hydrofluoroalkane134a metered | #5 |
| doses 8x | #5 |
| hfa cumulative doses | #5 |
| dosing asthmatic | #5 |
| 52 weeks regular | #5 |
| 95 16x dose | #5 |
| rate levalbuterol | #5 |
| dose racemic albuterol | #5 |
| regular levalbuterol | #5 |
| hfa cumulative | #5 |
| 16x dose | #5 |
| 16x levalbuterol | #5 |
| plasma ralbuterol | #5 |
| hfa administered | #5 |
| hfa levalbuterol | #6 |
| metereddose inhaler patients | #6 |
| hfa racemic | #6 |
| hfa mdi hfa | #6 |
| subjects levalbuterol | #6 |
| racemic albuterol hfa | #6 |
| levalbuterol hfa | #6 |
| levalbuterol hfa mdi | #6 |
| mdi asthmatic | #6 |
| dosing levalbuterol | #6 |
| 8x greater | #7 |
| cumulative dose study | #8 |
| hfa hfa mdi | #8 |
| ralbuterol plasma | #9 |
| mdi dosing | #9 |
| levalbuterol administered | #9 |
| safety levalbuterol | #10 |
| actuations 90 | #12 |
| greater racemic | #12 |
| hfa metered | #13 |
| 8x dose | #13 |
| mdi 90 | #13 |
| doses levalbuterol | #14 |
| inhalers spirometry | #14 |
| study levalbuterol | #16 |
| asthma adverse events | #16 |
| 90 microg dose | #17 |
Open the FULL List in Excel | |
Prominent publications by Kenneth Tripp
OBJECTIVE: To evaluate the efficacy and safety of levalbuterol metered dose inhaler (MDI) in children aged 4-11 years (n = 173).
RESEARCH DESIGN AND METHODS: Multicenter, randomized, double-blind 28-day study of QID levalbuterol 90 microg, racemic albuterol 180 mug, and placebo (2:1:1 ratio). Serial spirometry was performed on Days 0, 14, and 28. The primary endpoint was the double-blind average peak percent (%) change in FEV(1) from visit pre-dose; the primary comparison was with ...
| Known for Racemic Albuterol | Metered Dose | Patients Asthma | 90 Microg | Administration Inhalation |
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma
[ PUBLICATION ]
BACKGROUND: Previous studies have raised concerns regarding the safety of regular use of beta2-agonists for treating asthma. Few studies have explored the safety of at least 1 year of use of racemic albuterol, and none have examined long-term dosing of levalbuterol.
OBJECTIVE: To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma.
METHODS: Patients with mild to moderate ...
| Known for Racemic Albuterol | Patients Asthma | Term Safety | Beta Agonists | Administration Inhalation |
BACKGROUND: The short-acting beta(2)-agonists levalbuterol and racemic albuterol are available for administration through a hydrofluoroalkane-134a (HFA) metered-dose inhaler (MDI).
OBJECTIVE: This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects.
METHODS: This was a randomized, modified-blind, active-controlled, multicenter, 2-way crossover study. Subjects (n = 49) were randomized to 16 ...
| Known for Racemic Albuterol | Beta Agonists | Bronchodilator Agents | Short Acting |
Key People For Racemic Albuterol
Kenneth Tripp:Expert Impact
Concepts for whichKenneth Tripphas direct influence:Racemic albuterol, Asthmatic subjects, Levalbuterol hfa mdi, Levalbuterol racemic albuterol, Adverse events levalbuterol, Hfa mdi, 90 microg, Levalbuterol hfa.
Kenneth Tripp:KOL impact
Concepts related to the work of other authors for whichfor which Kenneth Tripp has influence:Racemic albuterol, Inhaled corticosteroids, Acute asthma, Lev rac, Anticholinergics children, Week safety.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |